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The Drugs Stop Here: A Public Health Framework to 
Address the Drug Shortage Crisis 
SHARONA HoFFMAN* 
INTRODUCTION 
I serve on the ethics committee of a promioent Cleveland hospitaL During one 
meeting in the fall of 2011, our Chair announced that our first agenda item would be 
the drug shortages that the hospital was facing. These included anesthetic and che-
motherapy agents needed by critically ill patients. Wnile this issue was sadly familiar 
to committee members who were long-time hospital employees, others were stunned 
how could such shortages plague premier hospitals in the twenty-first century in 
the wealthiest country in the world? How could even patients with comprehensive 
health insurance and abundant financial resources he denied adequate care because 
the medications they require are simply not available in the marketplace? 
Unfortunately, our hospital is not alone. The drug shortage crisis has increas-
ingly drawn the attention of the media and government authorities. In September 
of 2011, the FDA conducted a one-day Drug Shortage Workshop.! A front page 
New York Times story on January 1, 2012 focused on a national shortage of ge-
neric pills that treat attention deficit hyperactivity disorder (AOHD) and reported 
that it is affecting millions of patients2 A few weeks earlier, the Times published a 
story concerning the unavailability of Doxil, an important chemotherapy agent.' 
Thus far, little has been written in the law review literature about the drug short-
age crisis, and this article begins to fill this gap. It provides a thorough analysis of 
the origins and implications of the drug shortage problem and formulates a multi-
layered approach to addressing it. 
Part I of the Article describes the drug shortage problem. Part II analyzes the 
causes of the shortage crisis, including manufacturing difficulties, unanticipated 
demand, producers' economic calculations, and regulatory policies with unintended 
consequences. Part ill explores the very serious impact that drug scarcity has on 
patients and health care providers. 
Part IV argues that drug shortages result from a combination of market failures 
and regulatory constraints. However, because of the specialized nature of the health 
care market and the law price responsiveness that characterizes it, the problem 
cannot be fixed by the market alone v,1thout government involvement. The drug 
scarcity crisis should be considered a serious public health threat that requires 
vigorous government intervention under federal public health powers. 
Part V assesses a large number of recommendations that have heen offered by 
industry, government, and academic experts. While some suggestions are ill-advised, 
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a selection of others should be adopted. The Article posits that public health policies 
and standards must serve multiple roles. They should deter both carelessness that 
leads to product contamination and strategic decisions to discontinue or suspend 
manufacturing when such decisions will cause shortages. At the same time, govern-
mental rules should encourage production of vulnerable drugs. Accordingly, the 
Article proposes a blend of legislative, regulatory, and private-sector interventions 
that should realign manufacturers' incentives and significantly diminish the drug 
shortage phenomenon. 
I. THE DRUG SHORTAGE PROBLEM 
Serious drug shortages flrst emerged in 1999.4 The FDA defines drug shortages 
as occurring "when the total supply of all clinically interchangeable versions of a 
FDA-regulated drug is inadequate to meet the current or projected demand at the 
patient level."' The problem has become increasingly acute in recent years.' In 2005 
there were 61 reported drug shortage&' In 2010, the number increased to 1788 Medi-
cal products other than drugs, such as biologics' and devices, have also been subject 
to shortages but have garnered less attention from the media and policy-makers." 
Statistics may vary depending upon the focus of particular studies" For 
example, the American Society of Health-System Pharmacists (ASHP) takes 
into account all instances in which "a supply issue ... affects bow the pharmacy 
prepares or dispenses a drug product or influences patient care when prescrib-
ers must use an alternative agent." 12 The Food and Drug Administration (FDA) 
focuses more narrowly on medically necessary drugs that are "used to treat or 
prevent a serious disease or medical condition ... [for which] there is no other 
" FDA Workshop1 supra n<Jte 1, at 20. 
~ CDER MANUAL OF PoLICJES AND PROCEDURES MAPP 6003.1 at 2{2006}ravailable at http:J/www. 
fda.gov/do\vnloadsiAboutFDAJCcntersOffices/CDER/1v1anua!oiPoliL'iesProcedures/1JCM079936.pdf; 
Pre,otcrip!ion Drug Shortages: Examining a Public Health Concern and Potential Solutiom, Statement of 
Sandra Kweder, M.D. Before the Committee on HenJth, Education, Labor and Pensions, United States 
Senale, December 15,2011, at http://www.fda.gov/NewsEventsJTestimony/ucm2S2956.hun (hereinafter 
Kweder Statement]. Dr. Kweder is the Deputy Director of the FDA:s Office of New Drugs Center for 
Drug Evaluation and Research. 
6 Kevin Haninger et aL, Economic Analysis of the Cames of Drug Shortages 3 (Oct 2011)~ avaflable 
at http;f/aspe.hhs.gov/sp/report.s/20llldrugshortages/ib.pdf; Joseph M. Hill & Cynthia Reilly, Can rhe 
United Stat.es Ensure an Adequate Supply of Critical AfedicatioJtS? 1 FD LI's Fooo & DRUG Pot'Y FottuM 
I, 1 {August 24: 2011), available at http://y,.·'lv\v,fdlLorgipub!i/policyforurol (noting that "the number of 
shortages has nearly tripled since 2006" and that the number of shortages in 2011 was expected to be 
larger than the 2010 figure). 
1 U.S. Food-and Drug Administration, A Review of FDA's Approad1to lvtedicnl Product Shortages 
3 (October 31, 2011) [hereinafter FDA Review], available at http:/lwww.fda.gov/dQwnloads/aboutfdai 
reporumanualsforms/reports/ucm277755.pdf. 
8 I d.; Jocelyn Kaiser., Shortagrw of Cancer Drugs Put Parienls, Trials at Risk, 332 SclENCE 523, 
523 {2011) (noting that shortages "have tripled since 2006.,). 
'1 See U.S. Food and Drug Administration, Biologic Product Shortages, at http://\lrww.fda.gov/ 
BiclogicsBloodVaccines/Safety AvailabilitylShortages/default.htm. Biologics, unlike drugs are "derived 
from living sources (such as humans, animals, and microorganisms" and include "blood, vaccines., al-
lergenics, tissues, and cellular and gene therapies.~ US. Food and Drug Administration, About CBER, 
at http://www.fda.gov/AboutFDA!Ce.ntersOffices/OfficeoWedicatProductsandTobacco/CBER/ 
ucml23340.htm. 
10 FDA Workshop, supra note 1, at 41; C. Lee Ventola, The Drug Shortage Crisis in the United 
States: Causes, hnpact, and Managemenr Strawgies. 36 P & T740, 74l (2011) (indicating thal the US. 
has suffered from shortages of medical supplies). 
n Id (explaining why the University of Utah's statistics are different from the FDA's). 
11 Erin R. Fox et al., ASHP Guidelines on ;i{anaging Drug Product Shortages in Hospiwls and 
Health Systems, 66 AM. J. HEALTit-STn. PHARM. 1:399, 1400 (2009). 
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available source of that product or alternative drug that is judged by medical staff 
to be an adequate substitute."13 Thus, while. the FDA identified 178 drug short-
ages in 2010, the ASHP reported the number as 211. 14 Furthermore, according 
to the ASHP, as of September 2011, there had already been 210 medical product 
shortages in 2011. 15 
Certain drugs have been more vulnerable to shortages than others. When the 
FDA studied 127 drug shortages that were of long duration and had significant 
public health implications, it found that sterile injectables accounted for eighty 
percent of them. 16 The three most common classes of drugs in shortage were "on-
cology drugs (28%), antibiotics (13%), and electrolyte/nutrition drugs (II %)." 17 
Many commentators have decried the alarming dearth of some chemotherapy 
drugs in recent years." Others have noted that heart drugs, pain medications, at-
tention deficit hyperactivity disorder therapies, and anesthesia agents, have been 
in short supply as well." 
A recent survey found that forty-seven percent of hospitals with four-hundred 
or more beds experienced over thirty drug shortages in 2010.20 Fifty percent of 
respondents were affected by seven drug shortages, and three shortages affected 
over eighty percent of respondents21 Only one percent of respondents (four 
institutions) indicated that they were unaffected by drug shortages in 2010.22 
A second survey of 311 pharmacy experts from 228 hospitals and other health-
care facilities, conducted by Premier Healthcare Alliance, yielded equally startling 
results." Focusing on the period of July-December 2010, it found the following: 
89 percent [of pharmacy experts] experienced shortages that may have 
caused a medication safety issue or error in patient care. 
0 53 percent suggested occurrence 6+ times. 
1l Fox et al., supra note 12 at 1405; U.S. Food and Drug Administration, FDA and lvfanufacturers 
Work to Prevent Drug Shortages, at http://www.fdagov/Drugs!DrugSafety/DrugShortageslucm257746.btm. 
14 Ventola, supra note 10, at 740. 
15 Jd; FDA Workshop, supra note 1, at42. 
16 FDA Review, supra note 7, at4. 
17 Id 
18 Haninger eta!., supra note 6, at l; Mandy L. Gatesrnan & Thomas J. Smith, The Shortage of 
Essential Chemotherapy Drugs in the United States, 365 N. ENGL. J. MED. 1653, 1653 (2011); Steven 
Reinberg, Cancer Drug Shortages Getting Worse, FDA Says, HEALTIIDAY (August 24, 2011), available 
at http :1/yourlif e. usatoda y.com/heal th/story /20 11-08-28/Cancer -drug -shortages-getting-we rse-FDA-
says/50148996/I. 
19 Ventola, supra note 10, at 740 (listing heart drugs, pain medications, intravenous electrolytes, 
leucovorin, propofol, morphine, hydromorphone, furosemide, amino acids, and technetium-99m); Valerie 
Jensen & Bob A. Rappaport, The Reality of DrUg Shortages- The Case of the Injectable Agent Propofol, 
363 N. ENGL. J. MED. 806,806 (20!0) (discussing the critical shortage of propofol, "a fast-onset, short-
acting sedative-hypnotic agent used for the induction and maintenance of anesthesia or sedation."); Hill 
& Reilly, supra note 6, at 1 (listing "anti-cancer drugs, anesthetics, and nutritional therapies"); Harris, 
supra note 2, at AI (discussing the shortage of generic drugs to treat attention deficit hyperactivity 
disorder); Bruce A. Chabner, Drug Shortages- A Critical Challenge for the Generic-Drug .Market, 365 
N. ENGL. J. MED. 2147, 2147-48 (2011) ("The Jist of generic drugs in short supply across all medical 
specialties is astounding and includes antibiotics, anesthetic agents, antihypertensive medications, and 
common electrolyte solutions and vitamins."). 
w RaJa Kaakeh et al., Impact of Drug Shortages on US. Health Systems, 68 AM. J. HEALTH-SYST. 
PHARM. 1811, 1814 (2011). The survey was completed by 353 directors of pharmacy. Jd at 1811. 
11 Id at 1815. 
ll ld 
ll Coleen Cherici eta!., Navigating Drug Shortages in AmericanHealthcare: A Premier Healthcare 
Alliance Analysis 3 (March 2011), available at http://www.premierinc.com/aboutlnews/ll-mar/drug-
shortage-white-paper-3-28-ll.pdf (surveying pharmacy experts from hospitals as well as "infusion, 
oncology and surgery centers; outpatient and retail pharmacies; and long-term care facilities"), 
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80 percent experienced shortages that resulted in a delay or cancellation 
of a patient care intervention. 
0 34 percent suggested occurrence 6+ times. 
98 percent experienced shortages that resulted in an increase in costs. 
0 88 percent suggested occurrence 6+ times. 
0 41 percent suggested occurrence 21 +times." 
The drug shortage phenomenon is serious and pervasive. It is becoming an ines-
capable reality for many health care providers and millions of American patients. 
II. CAUSES OF DRUG SHORTAGES 
Numerous factors explain the medical product shortage phenomenon. According 
to the University of Utah Drug Information Service, 23% of shortages are caused by 
manufacturing problems, 13% are rooted in supply and demand changes, 6% occur 
because manufacturers discontinue production, 3% result from the unavailability of 
raw materials, and 55% of shortages are of unknown origin.'-' Information about 
drug shortage causes is often lacking because the FDA is not authorized to require 
manufacturers to explain shortages and must rely on voluntary reporting.'" This 
Part will loosely classify the causes of drug shortages as: manufacturing difficul-
ties, unanticipated demand, manufacturers' economic calculations, and regulatory 
policies witb unintended consequences. 
A. Manufacturing Hurdles 
Some manufacturers suffer disruptions stemming from the unavailability of raw 
or bulk materials." According to one estimate, the U.S. imports approximately 
eighty percent of raw materials used in pharmaceutical products.2' Consequently, 
supplies can be impacted by a variety of occurrences abroad, such as armed conflict, 
political unrest, animal diseases, and adverse environmental conditions."' American 
manufacturers can also experience difficulties at their U.S. facilities because of 
faulty equipment or human errors tbat lead to production delays, voluntary recalls, 
or FDA enforcement actions." In the past, for example, injectables were found to 
contain contaminants such as glass shards, metal filings, and fungus, and these 
impurities ultimately led to shortages." 
Natural disasters both within and outside of the United States can also affect 
product availability. Hurricanes, earthquakes, floods, and other catastrophes can 
~ Id. 
l! Ventola, supra note 10, at 741; Erin R. Fox, Drug Shortage Updare Curren! Status & Significant 
Trends, at http:l/www.fda.gov/downloads/Drugs!NewsEvents!UCM274565.pd£ 
~6 U.S. Food and Drug Administration, Currem Drug Shortages, at http://www.fda.gov/Drugs/ 
DrugSafety/DrugShoctageslucm050792.htm. 
:; }'Ox et aJ., supra note 12, at 1400; FDA Review, supra note 7, at 4 (indicating that "'active phar-
maceutical ingredient shortages" accounted for IW/a of reported shortages}. 
1l! Fox et al.; supra note 12, at 1400. 
~u 
:m Fox et aJ., supra note 12, at 1400; FDA Review, supra note 7, at 4 (indicating that "problems at 
the manufacturing facility" accounted for 43% of reported shortages); RobertSteinbrook, Drug Short~ 
ages and Public Health, 361 N. ENGL.l M£D. 1525, 1525 (2009) {discussing the ... viral contamination 
of a Gen;.yme Manufacturing plant in Massachusetts" that caused shortages of drugs for Gaucher's 
disease and Fabry's disease). 
Jl FDA Review, supra note 7, at 4, 
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damage production facilities, causing temporary or permanent shut-downs. In-
creased need for particular drugs in order to treat disaster victims in one location 
can also lead to scarcity in other regions." For example, drug shortages occurred 
in the aftermaths of the 1998 hurricane George that hit manufacturing facilities in 
Puerto Rico and the 2005 hurricanes Katrina and Rita." 
If a manufacturer is one of only a few suppliers or the primary supplier, even a 
temporary suspension of production can have a devastating market effect. Unfor-
tunately, some segments of the pharmaceutical market are not characterized by 
robust competition. For example, the top three manufacturers of generic injectables 
produce seventy-one percent of product volume, and commonly, a single manu-
facturer produces ninety percent or more of an individual sterile injectable drug34 
Many vaccines in the U.S. are manufactured by ouly one source." In some cases, 
mergers within the industry shrink the number of suppliers," as do small profit 
margins, discussed in more detail below." 
B. Unanticipated Demand 
Demand can increase unexpectedly because of new usage recommendations 
made by government authorities or by other experts who generate clinical practice 
guidelines." A pediatric flu vaccine shortage in 2006 resulted from the Centers for 
Disease Control and Prevention's new recommendation that children as young as 
6 months be vaccinated." Disease outbreaks may also raise demand unexpectedly 
and thus generate shortage~ 40 
Flexibility to meet demand changes is often limited because suppliers engage in 
"just-in-time" production and inventory practices that may exacerbate shortages." 
Limiting supply to meet ouly anticipated demand reduces vendors' storage costs 
and manufacturers' risk of being left with unsold product. However, "just in time" 
practices leave no surplus to create a cushion in case of shortages.'2 
C. Economic Calculations 
At times, manufacturers reduce or discontinue production because a medical 
product is not lucrative enough. Sterile injectable drugs are complicated to manu-
facture and often require dedicated manufacturing lines." Consequently, companies 
at times conclude that manufacturing such drugs requires them to absorb excessive 
fmancial and opportunity costs and decide to abandon the product line. 
51 Fox et aL, supra note l2, at 1402; Ventola, supra note 10, at 742. 
JJ Ventola, supra note IO, at 742. 
>i FDA Review, supra note 7, at4; see also. Kweder Statement, supra note 5 (stating that "[ijn 2010, 
the top five generic sterile injectable manufacturers accounted for 80 percent of the sterile injcctables 
sold in the US. marlr..et by volume."), 
Js Fox et al., note 24, at 1401, 
;!(; ld.; Valerie Jensen et al., FDA's Role in Respondfng to Drug Shortages, 59 AM. J. HEALTH-S-vsr. 
PHARM. ]413, 1424 {2002}. 
n See infra Part II.C. 
:re Fox et ar., supra note 12, at 1401. 
39 Ventola, supra note 10, at 742. 
"' Id 
" Jd 
42 Jd; FDA Review, supra note 7. at 4; Hill & Reilly, supra note 6, at 2. 
43 FDA Review, supra note 7, at4. 
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Shortages of generic injectables have been particularly common, and this phe-
nomenon has been attributable to high manufacturing costs and low profit margins'' 
For example, in 2008, the FDA approved the oncology drug levoleucovorin. The 
medication was no more effective than its generic form, leucovorin, and was fifty-
eight times as expensive, but its use became increasingly widespread." A shonage 
of the less costly leucovorin was reported eight months after the brand-name's ap-
proval because manufacturers were no longer interested in producing it.46 Similarly, 
in 2000, several vaccines, including those against diphtheria and tetanus, were in 
shortage because a manufacturer with low revenues discontinued production." 
Patent expiration has also been identified as a noteworthy cause of recent short-
ages." Since 2008, a large number of chemotherapy patents have expired!' \\'hen 
a drug's patent expires and generic drugs or other competing medications become 
available, the drug's price is likely to decrease. Lower revenues can drive manufac-
turers to change course and invest their resources in more profitable products."' 
Manufacturers of generic drugs may prefer to sell their goods abroad in order 
to earn greater profits. 51 In Europe, for example, generic drugs are sold at higher 
prices than in the U.S.'1 Manufacturers' diversion of supplies to foreign countries 
further contributes to shortages in the U.S. 
In the health care market, manufacturers are constrained in their ability to em-
ploy traditional techniques to reduce demand, increase profits, or quickly bolster 
supplies. The market is characterized by low "price responsiveness. "53 Producers 
of goods and services in other industries who wish to curtail supplies can diminish 
consumer demand by raising prices." By contrast, patient demand is often unaf-
fected by price changes because medically necessary drugs are critical to patients' 
welfare or even survivaL Moreover, suppliers are often powerless to raise prices in 
the short term because health insurers typically pre-negotiate reimbursement rates 
so that suppliers cannot alter prices during the contract term." 
At the same time, when demand rises in light of changed practice guidelines, 
manufacturers cannot always quickly increase supply because of the rigorous indus-
try and regulatory standards that manufacturers must meet. 56 The need for costly 
specialized equipment and complicated production processes may thwart quick 
acceleration of production, and new alternative products can take years to move 
through the clinical testing and FDA approval process." In addition, manufacturers 
are often loath to build excess production capacity, also known as "redundancy," 
in order to meet unanticipated demand increases, because doing so is costly and 
41 Hili & Reilly, supra note 6, at 4; Ventola, supra note to, at 742. 
43 Gatesman & Smith1 supra note 18, at 1653-54. 
"' Id. 
41 Vent-ola, supra note 10, at 742. 
48 Jensen & Rappaport, supra note 19, at 806. 
4
' Haninger et al., supra note 6, at L 
sc Jensen & Rappaport, supra note 19, at 806. 
S! Chabner, supra note 19, at 2149. 
!1 Gatesman &. Smith, supra note 18, at I 655. 
5! Hauinger et aL, supra note 61 at 34. 
54 Jd See supra note 13 and accompanying text for definition of medically necessary products. 
S$ Haninger eta!., supra note 6, at 4. 
~n Jd 
!1 U.S. Department of Health & Human Services, Statement by Sherry Glied Ph.D. Assistant 
Sf!.cretary for Planning and Evaluation US. Department of Health and Human Services ( HHS) on Pre-
scripritm Drug Shortages: Examining a Public Health Concern and Potential Solutions before Cummittee 
on Healrh, Educalion, Labor and Pensions United States Senate (December 15, 2011), at http:/lv,:-tvw. 
hhs.gov/aslltestify/2011112/t20111215c.html [hereinafter Glied Statement]. 
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earnings are speculative. Manufacturers prefer to invest their resources in producing 
therapies for which there is existing demand and that are likely to generate more 
immediate and certain profits." 
D. Unintended Consequences of Regulatory Policies 
Ironically, federal regulatory agencies also have a hand in contributing to short-
ages. The Drug Enforcement Administration (DEA) sets quotas for the manufac-
turing of particular drugs in order to control supplies and combat drug abuse. 59 
For example, the DEA subjects manufacturers of ADHD drugs to quotas because 
of concern that these drugs will be abused by non-disabled students seeking to 
enhance their concentration or by individuals who flnd that the medications' ef-
fect is a cocaine-like high. ro Manufacturers who are constrained by a quota may 
opt to produce a large amount of more expensive, higher-profit ADHD pills, and 
consequently produce too few of their cheaper, generic counterparts that are often 
favored by patients." 
The FDA's Unapproved Drug Initiative, launched in 2006, also created incen-
tives for some generic drug manufacturers to discontinue production. The initiative 
targets drugs that were introduced to the market before the FDA obtained drug 
approval authority in 1938 and aims to subject them to scrutiny under a fonnal 
approval process." Because ftling a New Drug Application can be a time-consuming 
and burdensome process, some manufacturers may opt to cease production of these 
older, often generic drugs rather than seek FDA approval." 
The Medicare reimbursement structure is an additional cause of shortages of 
chemotherapy agents because it incentivizes physicians to administer costly brand-
name drugs rather than generics."' Under the Medicare Prescription Drug, Improve-
ment, and Modernization Act of 2003 (MMA), oncologist reimbursement is set at 
the average sales price paid during the preceding two quarters plus six percent." 
Physicians who choose more expensive drugs thus receive a higher dollar amount 
than those who choose generics. To illustrate, six percent of Abraxane, whose price 
is $5,824, will yield a much higher payment for an oncologist than six percent of 
paclitaxel, which sells for $312.56 Lower demand for a generic chemotherapy drug 
may motivate manufacturers to abandon production so that patients and physicians 
who prefer the generic are unable to obtain it. 
A Department of Health and Human Services study that reviewed Medicare 
Part B volume of service data confirmed the association between sale volumes 
and shortages. It found that 44 drugs with declining sales in 2006-2008 were in 
s1 Haninger et al, supra note 6, at 4. 
;S9 Hill & Reilly, suprn note 6, at 4. 
00 Harris, supra note 2, at Al7. 
~~ !d. 
62 U.S. Food and Drug Administration, Unapproved Drugs Initiative, at http://wwv.·.fda.gov/Drugsl 
GtridanceComplianceRegulatorylnformation!EnforcementActivitiesbyFDA/SelectedEnforcementAc-
tionsonUnapprovedDrugs/ucmllB990.htm; Ventola, supra note 10, at 749. 
&l Ventola, supra note 10, at 749; Chcrici et aL, supra note 23, at 2. 
M Gatesman &Smith, supra note 18, at 1654. 
6! ld.; Mireille Jacobson eta!., How Medicare's Paymem Cuts for Cancer Chemotherapy Drugs 
Changed Patterns ofTrearmenl, 29 HE:\.LTif AFF. 1391, l392 (2010); Centers for Medicare and Medicaid 
Services, 2012 ASP Drug Pricing Files, at bttps://www.cms.gov/McrPartBDrugAvgSaJesPricelOlal7_ 
2012ASPFiles.asp (stating that payment amounts "are 106 percent of the Average Sales Price {ASP) 
calculated from data submitted by drug manufacturers" with "quarter to quarter price changes"). 
to Gatesman & Smith, supra note i8, at 1654. 
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shortage in subsequent years, and 28 drugs with increased sales in 2006-2008 were 
never involved in a shortage. 61 The study also found that the prices of the 44 drugs 
in shortage had steadily decreased, while the prices of the 28 drugs whose supply 
was adequate did not change significantly." 
ffi. IMPACT OF DRUG SHORTAGES 
Drug shortages can have devastating consequences for patients and health care 
providers. They can endanger patients, significantly increase health care expendi-
rures, and imperil medical research, among other consequences. 
A. Poor Treatment Outcomes 
Drug shortages often endanger the lives of patients. '¥\'hen health care providers 
cannot obtain needed drugs, they must ration care, delay treatment, and cancel 
procedures." Cancer patients may have to be triaged so that those with the best 
prognosis are given priority for scarce chemotherapy drugs, and others do not 
receive the medication of choice and may not survive. 70 
In September of 2011, the FDA held a Drug Shortage Workshop. 71 Michael 
Cohen of the Institute for Safe Medication Practices described an instance in which 
a patient died because he could not obtain Amikacin to treat an infection that was 
resistant to other antibiotics." Mr. Cohen also noted nine deaths that occurred 
in Alabama because patients were given parenteral nutrition infusions that were 
contaminated with bacteria when a pharmacy facing a shortage used an unfamiliar 
ingredient." He further stated that patients have awakened during surgery because 
their anesthesiologists were forced to use agents to which they were unaccustomed." 
Other speakers recounted additional problems resulting from anesthetic substitu-
tions, including longer recovery periods, agitation, delirium, and more frequent 
post~operative nausea and vomiting. is 
Thus, even when clinicians find adequate substitutes, drug shortages can lead 
to poor treatment outcomes or medical errors." In one survey, twenty-five percent 
of respondents indicated that an error bad occurred at their facility because of 
a shortage" Clinicians who are inexperienced with an alternative product may 
administer it incorrectly or provide a patient with the \\Tong dosage." 
t< Hanlnger et al., supra note 6, at 7~8. 
m Id at 8. 
ffl Ventola, supra note 10, at 750. 
10 fd. at 750-51; Susan Jenks, Efforts Underway to Curb Drug Shortages, 1031 NAT'L CANC£11. 
lNsrrr. 914, 914 (2011) ("In recent weeks, shortages in cytarabine injections raised the spe~ter ... of 
denying leukemia patients a chemotherapy drug carrying their best hope for survival"). 
11 FDA Workshop, supra note I. 
71 id. at 110. 
13 I d. at 115. Parenteral nutrition is given intravenously using customized, sterile formulas and 
a central IV line when a patient cannot eat and digest normally. Jd at 88~89. See also, Ventola. supra 
note 10, at 751 (describing the same incident). 
14 FDA Workshop, supra note 1, at 110. 
15 Id. at 142,248. 
16 Maryn McKenna, Hospital Pharn:acists Scrambling Amid Vast Dmg Shortages, 57 AN"NALS OF 
EMERGEKCY MEo. BA, 13A-i4A (2011) (describing medical errors including "a 20-fold overdose of 
dexmedetouridine bet:ause the staff were not familiar with dosing for the alternative drug"). 
77 Gatesman & Smith, supra note 18, at 1653. 
18 ld 
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At the FDA Workshop, several patients provided poignant accounts of their 
perso1:1al encounters with drug shortages." Jay Cuetam, a cancer patient, described 
his reaction when be learned that he would not be able to receive chemotherapy as 
scheduled because injectable 5-FU was unavailable: "At that point, I was dumb-
founded. The question I then asked myself was how in the United States of America 
could critical lifesaving or life-prolonging drugs be in short supply?" Sarah Batalka, 
a muscular dystrophy patient who requires intravenous electrolytes recalled suffer-
ing extreme anxiety when she learned of an inuninent shortage: 
In April of this year, I got the worst possible news. I was told by my home 
infusion pharmacy that their supply of IV magnesium sulfate, a key 
ingredient in my IV bags and one without [which] I cannot survive, was 
dwindling and that they only had enough to Iill my IV bags for a few more 
week[s]. To give you some idea of the impact this news had one [sic] me, 
please consider what it would feel like to you if someone told you there 
would only be enough air supply left for you for three weeks of breathing'" 
The number of deaths associated with drug shortages has not been tracked." 
The figure would be difficult to determine because of uncertainty as to whether 
particular patients died of their underlying disease or because of departures from 
standard therapy." There is no doubt, however, that drug shortages are significantly 
impacting treatment outcomes and costing patient lives. 
B. Increased Healthcare Costs 
A recent survey that was sent to health system pharmacy directors attempted to 
quantify the cost of drug shortages." The survey found that the estimated annual 
labor cost associated with drug shortages was $216 million." Pharmacists and 
pharmacy technicians spent eight or nine hours a week managing drug shortages 
by gathering, communicating, and processing information; identifying alterna-
tives; and managing inventory'' According to Scott Knoer, the Chief Pharmacy 
Officer of the Cleveland Clinic, the Clinic employs a fnll-time pharmacist for the 
sole purpose of addressing drug shortages and recalls'' 
In response to drug shortages, some vendors engage in the creation of "gray 
markets" and price gouging." Distributors buy up the remaining supply of a product 
and then sell it to health care providers at ten to one-thousand times the ordinary 
price." According to one source, in the case of cancer drugs, gray market vendors 
have charged markups of up to 3000%." 
79 Id. at83~10L 
so Id at 103. Fortunately, the patient's pharmacy was able to obtain additional supplies of IV 
magnesium sulfate, which she was stHI receiving at lhe time of ber testimony, However, the patient 
remained concerned about how she would fare in tb.e furore. Id, at l 05. 
n Ventola, supra note 10, at 75L 
u !d.; Jenks, supra note 62, at 914. 
n K.aakehetal,supranote20,at 1812. 
"Jd. atl814. 
n Id. 
66 FDA Workshop, supra note 1. at 329. 
1>1 Foxetal.,supranole-12,at !401. 
u Ventola, supra note 10, at 750. 
111 Gatesman & Smith, S'.J.pra note 18, at 1653. See also, FDA Workshop, supra note l, at 265 
(describing a markup of 4,500 percent in whicb a blood pressure medication that is normally priced at 
S25.90 was offered for $1200), 
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The pharmacy directors' survey estimated that U.S. hospitals spent at least 
$200 million on the purchase of more costly alternatives when supplies of cheaper 
drugs dwindled.90 These costs are likely attributable both to the replacement of 
generic drugs with brand-name medications and to gray market markups. Thus, 
drug shortages are estimated to cost U.S. hospitals a combined total of over $415 
million annually'' 
C. Adverse Impact on Medical Research 
Drug shortages can compromise the integrity of clinical trials and other re-
search endeavors. The success of clinical studies depends on careful compliance 
with research protocols. Unavailability of study drugs can cause enrolhnent to be 
postponed, research projects to be suspended or canceled, or research outcomes 
to be skewed." Reportedly, adult and pediatric cancer studies are in fact being 
hindered by drug shortages'' 
Also at issue is comparative effectiveness research (CER), which has been pro-
moted in recent federal legislation'' In 2009, Congress allocated $1.1 billion in 
funding forCER, as part of the American Reinvestment and Recovery Act." The 
Patient Protection and Affordable Care Act of 2010 (PPACA) embraced CER as an 
important health care reform initiative and established the Patient-Centered Out-
comes Research Institute to oversee CER in the United States."' CER is defined as 
"research evaluating and comparing health outcomes and the clinical effectiveness, 
risks, and benefits of 2 or more medical treatments, services, and items .... "97 The 
goal of such research is to generate improved patient outcomes while maximizing 
the value derived from health care expenditures. CER, however, will be unproduc-
tive if the research is hindered by shortages or if manufacturers opt to discontinue 
production of drugs that are found to be both effective and inexpensive because 
suppliers seek a larger profit margin. 
D. Other Consequences 
Drug shortages have further implications for physicians and patients. Doctors 
face the unenviable task of having to explain to patients that they cannot provide 
them with a needed drug or must replace a drug that has previously worked welL 
Patients may consequently lose trust in their doctors or switch to different practic-
es." In other cases, facilities may have to turn new patieots away because they do 
not have enough medication to treat their existing patients and, .therefore, cannot 
accept additional ones. 
90 Chcrici et al., supra note 23, at 7. 
\ll FDA Workshop, supra note 1, at 264. 
92 Id at 752; Kaiser, supra note 8, at 523 ("Shortages can also complicate ciinJcal trials 11}. 
91 FDA Workshop, supra note 1, at 123; Kweder statement, supra note 5. 
~ Sharona Hoffman & Andy Podgurski 1 Improving Health Care Outcomes through Personalized 
Comparisons of Treatment Effectiveness Based on Electronic Health Records, 39 J. L. MED. & Ent1cs 
w.w~I~ · 
'iS American Recovery and Reinvestment Act of 2009, tit. VITI, Pub. L No. 1 i 1-5, 123 Stat 115, 
177-78 (2009). 
~6 Patient Protection and Affordable Care Act of 20!0, Pub. L. No. 111-148, §6301 1 124 Stat. 119 
(2010), C<Jdifted at 42 U.S. C.§ !320e (2006). 
~ 42 U.S. C. §l320e(a)(2)(A) (2006). 
» Ventola., supra note 10, at 752 (discussing strained professional relationships). 
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Additionally, insurers may refuse to cover a treatment that has been substituted 
for a drug in shortage because the alternate medication does not constitute stan-
dard therapy." For patients who cannot pay out-of-pocket, an insurer's unfavorable 
decision can be a death sentence. 
IV. DRUG SHORTAGES AS A PUBLIC HEALTH CRISIS 
The drug shortage crisis is rooted in a combination of market failures and 
regulatory constraints. The problem cannot be corrected without governmental 
intervention, which would be justified by federal public health powers and a long 
history of federal initiatives to address serious public health threats. 
A. Regulatory Constraints and Market Failures 
Drug shortages arise because of both market failures and regulatory failures. 
First, government regulations in several arenas may inadvertently contribute to 
shortages. The FDA:s thorough drug approval process and enforcement actions 
in response to manufacturing problems that endanger patients can delay, slow, or 
suspend production.'"" The Medicare reimbursement scheme has also been blamed 
by many commentators for skewing drug purchasing incentives in ways that lead 
to shortages of less costly generic medications."' DEA quotas for controlled sub-
stances may further exacerbate the scarcity problem.'"' 
Much of the drug shortage crisis, however, is due to the limits of government 
involvement rather than to its excesses. The FDA cannot require manufacturers to 
produce drugs that are in short supply. 103 Thus, it cannot stop drug manufactur-
ers from making decisions in their own best interest even when these conflict with 
patients' interests. Because cheaper generic drugs are not necessarily the least ex-
pensive drugs to produce, 10' manufacturers at times opt to minimize or discontinue 
production wheo generics do not generate sufficient income. Such decisions can be 
made despite robust demand for the products on the part of clinicians and patients. 
Furthermore, the health care market is relatively inflexible and constrained in 
its ability to react effectively to supply and demand changes. Inadequate supplies 
do not necessarily reduce demand for drugs because patients cannot control what 
illnesses they suffer and what treatments they require. Manufacturers are also often 
powerless to raise prices in order to influence demand because of pre-negotiated 
terms with private and public insurers.'0' New manufacturers cannot quickly enter 
the market to increase supply because of strict regulatory requirements.106 Finally, 
clinicians often cannot fmd equally effective alternatives because some drugs are 
produced by a single source, or substitutes have unacceptable side·effects for par-
ticular patients.107 
"; FDA \Vorkshop, supra note!, at 248. 
100 See US. Food and Drug Administration, The FDA's Drug Review Process: Ensuring Drugs Are 
Safe and Effective, at http:l/wwwJda.gov/drugs/resourcesforyou!consumers/ucml43534.htm. 
161 See supra nol.es 58-60 and accompanying tex.L 
1c1 See supra note 53-55 and accompanying text 
103 Veniola, supra note 10, at 7:52; Jensen & Rappaport, supra note 19, at 807, 
uu See supra note 39 and accompanying texL 
1m. See supra note 49 and acwmpanylng text. 
100 U.S. Food and Drug Administration, supra not.e 91. 
m See supra note 30 and accompanying text; FDA Workshop, supra note 1~ at 82-87 (providing 
an account of a patient who suffered excruciating side effects from a substitute chemotherapy agent), 
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The unique nature of the health care market often makes it impossible for industry 
to rectify market problems through traditional supply and demand mechanisms 
and without the support of government involvement. In addition, the safety-critical 
nature of most medical treatments makes regulatory oversight vital to public health 
and welfare. 
B. Public Health Powers 
The federal government has considerable authority to address public health con-
cerns.'" Under Article 1, Section 8 of the Constitution, the federal government has 
the power to tax, spend, and regulate commerce among the various states. 109 Taxes 
and tax credits may be used as incentives to promote public health goals-' 10 Budget 
resources are routinely allocated to benefit public health."' And the government, 
through regulatory measures, oversees numerous private sector activities that affect 
public health.'" The production and marketing of drugs and medical devices has 
been subject to rigorous federal regulation for nearly seventy-five years under the 
Food, Drug, and Cosmetics Act of 1938 (FDCA). 113 
The federal government bas undertaken extensive initiatives in the area of public 
health emergencies.'" It has enacted numerous Jaws designed to facilitate disaster 
response activities and minimize casualties. Examples are the Emergency Manage-
ment Assistance Compact,'" Section 1135 of the Social Security Act,'" the Public 
Readiness and Emergency Preparedness Act,' 11 and the Project BioSbield Act of 
2004."' The drug shortage crisis can be compared to a public health emergency 
because of its large-scale public health implications. None of the traditional emer-
gency preparedness laws would be applicable because they are generally tailored to 
natural disasters and pandemics. 119 Nevertheless, these laws set important precedents 
for vigorous government action to address public health threats. 
C. Initial Public Health Responses to Shortages 
The federal government has not adopted a hands-off approach to drug short-
ages. The FDA has made the most of its existing powers and implemented several 
response measures. In addition, President Obama issued an executive order urging 
100 LAwRENCE.O. Go,:, !IN, PunucHEAt.:rH Ll·,w: PowER, DUTY, REsntA1NT 35 (2000) 
109 U.S. CoNsr. art. I, §8, cL 1, 3. 
1111 GoSTIN, supra note 99, at 35-38. 
10 ld.. at 38-40. 
11 l Id at 35,40-41. 
"'21 u.s. c.§§ 301-399 (2006). 
114 Sharona Hoffman, Responders' Responsibility: Liability an.d Immunity in Public Health Enter-
gencies, 96 GEo. L. J, 1941-46 (2008). 
n~ H.RJ. Res. 193, l04th Cong., §, 11{} Stat. 3877 (1996) (establishing a mutua] aid agreement that 
has been enacted by all states that is triggered by a governor'$ declaration of emergency and request for 
assistance). 
"' Pub. L No. 107-!88, § 143(a), 116 SiaL 594,627-29 (2002) (codified at42 U.S.C. § 1320b-5 (2006) 
{authorizing the Secretary of Health and Human Services to waive or modify certain legal requirements 
that apply to healr.h care providers furnishing goods and services in an emergency area). 
111 42 U.S.C.A. § 247d~6d (2006) {addressing immunity from liability relating to the administration 
and use of covered emergency eounterm.C"dSUres}. 
"' Pub. L. Nc. !08-276, 118 Stat. 835 (2004)(codified at42 U.S.C.A ~247d-6a (2006 & West Supp. 
2011) (providing that during a declared emergency1 !.he Secretary of Health and Human Services may 
authorize the emergency usc of a product that is not yet "approved, licensed, or dcared for commercial 
distribution"). 
111 See Hoffman, supra note I 06, at 1922, 194 I -42, and 1945-46. 
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federal authorities to stretch their existing powers to their limits. These measures 
are effective first steps, but they are inadequate to fully resolve the crisis. 
The FDA asserts that it helped prevent thirty-eight shortages in 2010 and 
ninety-nine shortages as of October 31, 20 II."" In order to decrease the number 
of future shortages or end current ones quickly, the FDA has expedited its review 
of submissions related to new manufacturing sites, suppliers, and specification 
changes."' The FDA also urged companies to increase production and worked 
with manufacturers to mitigate the dangers of safety problems.121 For example, 
when a manufacturing change Jed to the formation of crystals in vials of cytara-
bine, the FDA worked with the manufacturer to discover that the crystals could be 
dissolved through warming and permitted manufacturers to ship the product with 
special instructions for clinicians.'" When foreign particles were found in sodium 
phosphate, an electrolyte used in IV nutrition therapy, the FDA verified that the 
contaminants could be removed with fJ.!ters and permitted the supplier to ship the 
product so long as it provided instructions concerning the need for fl!tering.'" On 
rare occasion, the FDA may also allow a drug or its equivalent to be imported from 
a foreign country until the shortage is resolved in the U.S."' 
On October 3!, 2011, President Obama issued Executive Order 13588 entitled 
"Reducing Prescription Drug Shortages."'" The order directed the FDA "to use 
all appropriate administrative tools" to require manufacturers to provide adequate 
notice of their intention to discontinue manufacturing drugs in cases that could 
result in shortages of medications that support or sustain life or "prevent debilitat-
ing disease.""' Furthermore, the order instructed the FDA to bolster its efforts to 
expedite reviews of "new drug suppliers, manufacturing sites, and manufacturing 
changes" when such efforts may positively impact shortages.'" Finally, President 
Obama directed the FDA to report to the Department of Justice (DOJ) any fmdings 
that market participants are stockpiling scarce drugs and selling them "at exorbitant 
prices."'" While gray market sales are not themselves illegal, the DOJ and other 
regulatory authorities are to take appropriate enforcement actions against any 
parties found to have engaged in unlawful behavior, such as by violating antitrust 
laws or FDA regulations130 
Still, national shortages persist to the great detriment of patients. m The shortage 
crisis constitutes a serious public health threat that merits a much more aggressive 
federal government response. 
V: RECOMIVIENDATIONS 
There is no single solution that can resolve the drug shortage crisis. In partnership 
;vith industry, regulatory authorities must undertake a multi-faceted approach to 
l:W FDA Review, supra note 7, at 4. See also, Kwcder Statement, supm note 5 (asserting that by 
December 15th, the FDA had prevented 195 shortages in 20ll), 
111 FDA Review, supra note 7, at4. See also, Jensen et al 1 supra note 32, at 1424-25. 
121 FDA Review, supra note 7, at 4. See also, Jensen et aL, supra note 32, at 1424-25. 
m Kweder Statement, supra note 5. 
!:M !d. 
115 Jensen et at, supra note 32, at 1425; Jensen&: Rappaport, supra note 19, at 807 (noting that ln 
response to a propofol shortage, the FDA "temporarily allowed the importation into the United States 
of the unapproved drug Fresenius Propoven l~'u, a propofo! product approved in other cnuntries"). 
125 Exec. Order No. 13,588, 76 Fed. Reg. 68295 {Nov. 3, 2011). 
rn /d.at§2. 
lll Id at§ 3. 
1! 9 !d. at§ 4. 
JJO fd 
1; 1 See supra Parts I and IlL 
' ''~9"* 'T $ - 11 it !! iH 
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attack the problem. A blend of carrots and sticks should be used to achieve several 
goals: manufacturers must be incentivized to reach production levels that meet 
demand in the health care marketplace, and they must be deterred from intentional 
or negligent conduct that could lead to shortages. 
This Part critiques a variety of solutions that have been proposed by industry, 
government, and academic experts. They include: l) bills that would require advance 
notification for anticipated shortages; 2) amendment of the Hatch-Waxman Act; 3) 
creation of a national stockpile; 4) regulatory changes to the Medicare reimbursement 
system and DBA quotas; and 5) use of other fmancial incentives such as tax benefits, 
reduction in user fees, liability protection, and failure-to-supply contract clauses. 
A. Legislative Mandate Requiring Advance Notification for 
Anticipated Shortages 
In most instances, manufacturers are not required to notify the FDA of immi-
nent shortages.m Currently, the agency can require a six-month advance notifica-
tion only in cases in which sole manufacturers of drugs that are "life-supporting," 
"life-sustaining," or used to prevent debilitating diseases plan to discontinue pro-
duction."' In all other instances, absent voluntary reporting by industry, the FDA 
may remain ignorant of a shortage until it receives complaints from doctors who 
are grappling with it. 
Proposed legislation is designed to ensure that the FDA consistently receives 
advance notice of all shortages that can be anticipated. The "Preserving Access 
to Life-Saving Medications Act of 2011" was introduced as bi-partisan legislation 
in 2011 by Senator Amy Klobuchar aud Representative Diane DeGette. 134 The 
House and Senare bills would amend Section 506(c) of the FDCA."' They gener-
ally would require drug manufacturers to inform the FDA of known production 
discontinuances or disruptions six months in advance or as soon as they become 
aware of the possibility of a shortage if six months notice cannot be given.'" The 
legislation also provides for the imposition of civil penalties on manufacturers . 
that fail to comply with the notice requirements'" Furthermore, the proposed 
legislation instructs the FDA to do all of the following: I) distribute information 
about shortages to providers and patient organizations; 2) prioritize inspection of 
facilities involved in the production of drugs that have been subject to shortages; 
3) "implement evidence-based criteria" to identify drugs vulnerable to scarcity; and 
4) collaborate v.ith manufacturers to establish contingeocy plans for addressing 
shortages of these vulnerable drugs."' 
In order to protect manufacturers' interests, the bills establish a confidential-
ity mandate. They provide that disclosures concerning planned manufacturing 
discontinuations or interruptions will be treated as trade secrets or confidential 
information. 139 
m Jensen et al., supra note 32, at 1424. 
"' 21 U.S. C. §356c {2006). 
1~ H.R. 2245, llllh Cong, (20 11) and S, 296t ll2d' Con g. {2011) athttp://www,govtrack.us/congress/ 
billtext.xpd?bili:::::h 112~2245; http:f(www.govtrack.usfcongrcsslbiUtext.xpd7bill=sll2-296. 
"' 21 U.S. C. §356c (2006). 
"' H.R. 2245 at §506C(b)(l)-(5); S. 296 at §2(a)(2)-(S). The hills also establish exceptions to the 
standard notification requirements. 
'" H.R. 2245 at §506C(b)(7); S. 296 at §2(a)(6). 
'" H.R. 2245 at §506C(c); S. 296 at §§2{d) and (3). 
'" H.R. 2245 at §506C(b)(6); S. 296 at §2(b). 
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The proposed legislation's future is uncertain. The Senate and House bills were 
referred to committee in February and June of 2011 respectively, but neither has 
progressed beyond that point.'"' Moreover, the Republican majority in the House 
of Representatives is unlikely to support the bill because of apposition from the 
pharmaceutical industry and philosophical objections to more stringent regulatory 
requirements.141 
The stalled legislative process is unfortunate because the law would constitute a 
positive step in combating the drng shortage problem. The legislation would sig-
nificantly bolster and extend President Obama's executive order, which allows the 
FDA only to use currently appropriate tools to induce manufacturers to disclose 
anticipated shortages. Absent new legislation, the FDA does not have an adequate 
statutory disclosure mandate at its disposal. Advance notice would enable the FDA 
to work with industry to find alternate manufacturers who are willing to increase 
supplies or commence production and to expedite review of relevant submissions 
to help avoid drug scarcity. The FDA could also identify alternatives and prepare 
informational and training materials that could be distributed to clinicians in case 
the shortage materializes. Finally, if the FDA reliably determined which drngs are 
vulnerable to shortages because of particularly complex manufacturing processes 
or extremely low profit margins, it could more strategically intervene to prevent 
shortages. The fmancial incentives described in Part V.D below could be especially 
valuable in this regard. 
Some have expressed concern that early notice legislation would promote hoard-
ing and gray market activities."' Those noping to profit from drug scarcity may try 
hard to find sources that will leak information about shortages as early as possible. 
The legislation addresses these fears through its confidentiality mandate, which is 
designed to keep the public from learning about anticipated shortages at the time 
they are disclosed to the FDA. "' If the legislation is enacted, both manufacturers 
and the FDA would need to be committed to maintaining confidentiality and to 
preventing leaks. 
While the proposed statute would constitute a constructive step towards over-
coming the drng shortage problem, it is far from a comprehensive solution. It 
addresses planned production cessations or interruptions but not unanticipated 
manufacturing problems. 
One"improvement would be a requirement that manufacturers report all short-
ages, including unanticipated ones, to the FDA and provide explanations of their 
causes. This information would enable the FDA to build a database and analyze 
the reasons for various shortages in order to formulate solutions or to recommend 
appropriate courses of action to other parties. Currently, experts are constrained 
by a dearth of data and, more often than not, are unable to ascertain why short-
ages occur.'" Rigorous reporting requirements should arm policy-makers with 
knowledge they can use to attack the problem more effectively. 
An additional limitation is that the proposed legislation explicitly leaves the 
FDA powerless to force manufacturers to produce drugs or to revoke decisions 
14o http ://www.govtrack. uslcongresslbiiLxpd?bill-s 112~296; h ttp:l/www. govtrack. us/congress/bill, 
xpd?bill=hll2-2245. 
141 Ventola, supra note lO, at 755; Stephen Barlas, Severe Drug Shortages Impose Heavy Casts on 
Hospital Phannacies: Semue Bill Might Help ... or i'lat, 36 P&T 242,242 (201 i). 
141 Bar las, supra note 13 i, al 302. 
141 See supra note 129 and accompanying text. 
144 See supra note25 and accompanying text (stating that 55-!1f{Jof shortages are of unknown origin), 
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to suspend or discontinue production.'" Therefore, in many cases, the legislation 
will not allow the FDA to achieve an expeditious and permanent resolution to a 
shortage problem. Producers that have decided a particular drug is not sufficiently 
profilllble146 may often be immune to pressure from the FDA.141 
B. Hatch- Waxman Act Amendments 
The Drug Price Competition and Patent Term Restoration Act, also known 
as the Hatch-Waxman Act in honor of its two Congressional sponsors, is a 1984 
amendment to the FDCA, '"It enables manufacturers to file Abbreviated New Drug 
Applications (ANDA) with simplified requirements for generic medications.'" Some 
have suggested that the Hatch-Waxman Act be revised to require manufacturers to 
include projections concerning demand for their product and plans for meeting this 
demand and that the FDA be authorized to revoke marketing licenses if minimal 
production goals are unmet. "'Thus, generic drug manufacturers would be required 
to have redundancy capacity so that problems with particular sites, equipment, or 
a portion of the supply would not create catastrophic sbortages.m 
Furthermore, at least one expert has recommended that ANDA licensees who 
have consistently met market demand be awarded priority for any future ANDA 
submissions.'" In addition, the FDA could consider drug shortages as a factor in 
assessing ANDA filings and deem them to weigh against approvaL"' 
The Hatch-Waxman proposal would constitute a very aggressive intervention. By 
empowering the FDA to require redundancy and to revoke the licenses of companies 
whose production rate was inadequate, the legislation would depart significantly 
from current federal policy that prohibits the FDA from controlling manufacturers' 
decisions concerning quantity or continuation of production.'" Such a proposal 
would likely meet vigorous industry resistance and may be unrealistic. 
In addition, manufacturers may not be able to project demand for their product 
because of multiple factors that are outside their control. For example, produc-
ers cannot anticipate changes in clinical practice guideliues, natural disasters, or 
difficulties experienced by competitors that decrease their output and increase 
demand for supplies from other manufacturers.'" Moreover, arguably, depriving 
manufacturers of the liberty to reduce or discontinue production in the face of 
adverse fmancial conditions may be counterproductive and further discourage 
companies from entering the generic drug market in the frrst place. 
'" H.R. 2245 at§506C(c)(4)(b). 
145 See supra Pan TI.C, 
147 But see Ventola, supra note 10, at 753 (stating that in the face of shortages. the "FDA has been 
fairiy successful in influencing manufacturers to increase production" and that "[s]ome companies have 
even produced drugs at a loss, because they recognized a ~:ritical need for them). 
148 21 US. C. §355(j). See generally, Gerald J. Mossinghoff, Overview of rhe Hard1~Waxnum Act 
and Irs Impact an the Drug Dew!lopment Process, 54 Fooo& Dauo L J. 187 (1999). 
'" 21 u.s. c. §355(J)(2) 
Hu Chabner, supra note 19, at 21413. 
"
1 ld See also, American Society of Health~System Pharrnacisl:HR a1., Drug Shortages Summit 
November 5, 2010 Swnnw.ry Report4 (10 11) at http://w"'w.asbp.org/drugshortages/summitreport (sug-
gesting that 'the FDA "[r]eguire manufacturing redundancies (e.g., multiple manufacturing shes for a 
sole product or :multi pie [active pharmaceutical ingredients} API sources, when available) as part of ..• 
[its] approval process"). 
~~ Cbabner, .supra note 191 at2148. 
1 ~l Id. at 2.148-49. 
t~ See supra notes 95 and 134 and accompanying text, 
U$ See supra Part U (discussing causes of shortages). 
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Nevertheless, the proposal contains several laudable recommendations. The 
FDA would be well-advised to require applicants to indicate whether and how 
they will create redundancy in manufacturing capacity to avoid shortages in case 
of unplanned manufacturing difficulties. Redundancy would not be mandated but 
could be considered as a factor favoring approvaL ln addition, a past history of 
causing an avoidable shortage could be taken into account as a negative indicator 
if the manufacturer seeks approval of a new drug. Such a policy would aim to de-
ter both carelessness that leads to product contamination and strategic decisions 
concerning product discontinuations or suspensions. These changes in policy could 
be incoi:porated into the FDCA through amendment and need not be restricted 
to generic drugs. 
C. Creation of A National Stockpile 
A national stockpile of medically necessary treatments is an option that has been 
considered by several commentators-"' This approach would follow a precedent 
set for purposes of emergency preparedness. The Centers for Disease Control and 
Prevention has created a Strategic National Stockpile (SNS) that includes large 
quantities of medicine and medical supplies likely to be needed during a public 
health emergency. 157 SNS supplies are to be delivered to the states, which in turn 
are to quickly deliver them to local communities in accordance with emergency 
preparedness plans.'" 
Several obstacles stand in the way of building a national stockpile of drugs that 
are vulnerable to shortage. First, in some cases, it would necessitate collection of 
supplies that are already scarce and currently needed in clinics rather than in stor-
age.'" Second, constructing and maintaioing a national stockpile would require 
very significant financial and human resources and is logistically complex.'"' Finally, 
drugs have a limited shelf-life and must be replaced periodically. This means that 
staff will need to track the expiration dates of all supplies, and many drugs will go 
to waste if shortages do not materialize and they are not used in time.'" In light 
of shrinking federal resources and intense concern about the deficit, a national 
stockpile initiative is inadvisable at this time. 
D. Regulat01y Changes 
Administrative agencies should utilize their regulatory powers to combat the drug 
shortage crisis. This section considers potential changes to the Medicare reimburse-
156 A:Uierican Society of Health-System Pharmacislsetal.1 supra note 140, at 7; Lars Noah, Triage 
in the Nation's Afedicine Cabinet: The Puzzling Scarcity of Vaccines and Other Drugs, 54 S. C. L. REV. 
74!, 765-66 (2003). 
111 Centers for Disease Control and Prevention Office of Public Health Preparedness and Response, 
Strategic National Stodcpile (SNS) 1 at http:!/www,cdc.gov/phpr/stockpilclstockpile.htm [hereinafter 
CDCOPHPRj. 
UJ Id 
m American Society of Health-System Pharmacists et at, supra note 140, at 1, 
1611 Noah, supra note 144, at 766; CDC OPHPR, supra note 145. 
~<H CDC OPHPR, supra note 145 (stating that "{t]he SNS Program ensures that the medical 
materiel stock is rotated and kept within potency shelf~life limits, This involves quarterly quality ns-
suranre/quality control checks (QA/QC's) on all 12-hour Push Packages, annuallOO'/O'inveutory of aU 
12-hour Push Package items, and inspections of environmental conditions, security, and overall package 
maintenance''); Ventola, supra note 1.0, at 756 (arguing against stockpiling by individual health care 
facilities). 
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ment system and DEA quota requirements. Regulatory policies should encourage 
manufacturers to produce generic drugs that are often favored by patients because 
tbey are botb effective and inexpensive. 
L Revise Medicare Reimbursement System 
Several commentators assert that the Medicare reimbursement system must 
be altered so tbat prescribers do not have financial incentives to make treatment 
choices that are likely to lead to shortages.'" Medicare payments of six percent 
above tbe average sales price may induce oncologists to select expensive brand-
name drugs in order to maximjze the yield of tbe six percent markup.'" Minimal 
purchases of generics by physicians treating the elderly population may discour-
age manufacturers from producing generic drugs that would be the best choice for 
non-Medicare patients. 
The current reimbursement system was established in order to contain Medicare 
costs, and budgetary savings remain a crucial necessity. Before 2003, Medicare paid 
ninety-five percent of the average wholesale price (AWP) for chemotherapy drugs, 
a price set by manufacturers without regulatory pricing constraints. In reality, 
oncologists typically paid only between sixty-six and eighty-seven percent of -the 
AWP, which translated into an annual overpayment of approximately $1.6 billion 
by Medicare.'"' 
There is an inevitable tension between public programs' cost containment goals 
and providers' need to ensure tbe profitability of tbeir practices. The Centers for 
Medicare and Medicaid Services, however, should continue to revisit its reimburse-
ment policies, and, to tbe extent possible, revise them to avoid creating perverse 
incentives for clinicians. One possible solution is a payment system based on 
disease-management fees ratber than on chemotherapy sales."' The severity of the 
problem could also perhaps be diminished through a greater shift to fixed physician 
salaries."' Fixed salaries would remove individual physicians' incentive to select 
particular drugs in order to maximize Medicare reimbursement, though doctors 
may nonetheless face institutional pressure to do so. There is also some concern 
tbat tbe prospect of earnings based on salary alone would make tbe practice of 
oncology less profitable and appealing to talented medical students."' 
2. Alter DEA Quotas 
The DEA should establish a mechanism to increase production quotas for con-
trolled substances found to be in short supply or vulnerable to shortage, such as the 
attention deficit hyperactivity medications that were reportedly scarce in 201 L "' 
The Justice Department bas already noted that the quota regulations "have not 
111 Brouwyn Mixter, SelL Hatdt Developing Eillw Address 'Growing Crisis' of llfedicine Shortages, 
19 HF.AL'lll CARE PoL'Y REP. 1880, 1880 {201!); Gatesman & Smith, supra note 18, at 1655; Cbabncr, 
supra note 19, at 2149. 
163 See supra notes 58~60 and accompanying text. 
164 Gatesman & Smith, $Upra nate 18, at 1654; Renee Twombly, _Medicare Cost CoMain.ment Strategy 
Targets Several Oncology Drugs, 96 J. NAT'L CANCER lNST. 1268, 1268 (2004). 
tos Gatesman & Smith, supra note ]8, at 1655. 
!llfi Jd (noting that "KaiserPermanente, Veterans Affairs, and most acadern.iccenters" already pay 
their physicians salaries). 
1&1 Jd 
l&ll See supra notes 2, 53~ 55 and accompanying text; Hill & Reilly, ;supra note 6, at 4. 
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been reviewed or revised since they were first implemented in the early 1970's."'" 
It plans to re·evaluate the quota regulations under its Retrospective Analysis of 
Existing Rules."' 
E. Influence Manufacturer Conduct through Taxes, User Fees, and 
Other Incentives 
Policy-makers should consider several other strategies to address the drug 
shortage crisis. Under our free-enterprise system, manufacturers are at liberty to 
decide which goods to produce, and the government cannot dictate that they supply 
particular products.111 Consequently, appropriate incentives and disincentives must 
be in place to ensure that manufacturers voluntarily choose to produce sufficient 
supplies of drugs. 
The federal government could establish tax incentives to reward manufacturers 
for producing drugs that are in short supply or that are identified by the FDA as 
vulnerable to shortage. 172 An FDA initiative designed to ascertain which drugs are 
vulnerable, such as that proposed in the "Presen~ng Access to Life-Savings Medi-
cations Act of 2011," would facilitate implementation of a tax incentive program. 
The FDA could also build incentives into its fee programs. The Prescription 
Drug User Fee Act (PDUFA} was first enacted in 1992 and is renewed every five 
years. 173 It authorizes the FDA to collect fees from manufacturers of certain drugs 
and biological products, which are used to expedite the drug approval process. 174 
The FDA is contemplating adding a generic user fee program to the PDUFA:s 2012 
reauthorization. 115 The goal of the program would be to generate funds that would 
enable the FDA to reduce approval time from thirty months to ten months.'" Bring-
ing new generic drugs to market more quickly could itself eliminate some short-
ages, and the prospect of a short approval process may encourage some members 
of industry to undertake production of generics. 171 The fees themselves could be 
used as an added inducement mechanism. The FDA could award fee reductions 
or exemptions in select cases in which producers will increase the supply of vul-
nerable or scarce drugs.'" This would be consistent with PDUFA:s current policy 
of exempting applications for "orphan drugs" that treat rare diseases in order to 
incentivize their production.'" 
A different suggestion was made by Professor Lars Noah in a 2003 article. 
Professor Noah recommended that Congress enact legislation to reduce manu-
facturers' liability exposure, which theoretically might drive suppliers out of the 
l-69 Department of Justlce. Final Plan for Retrospective Review of Existing Regulations Pursuant to 
Executive Order 13563, at 14 (August22, 2011), available at http://www.justice.gov/open/doj-rr~linal­
plan.pd[ 
na Id 
111 See supra note: 95 and accompanying text. 
1n Hill & Reilly, .supra note 6, at 4; Mixter, supra note 150 at 1880. 
m Puh. L. No. 102-57l, 106 Stat. 4491 (1992) (oodified primarily at 21 U.S.C.A. §§ 379g, 379h); 
U.S. Food and Drug Administration, The Prescription Drug User Fee Act, at http://www.fda.gov/Fo-
r Industry/U serFees/Prescri plio nDru g User Fee/def a ul t.htm. 
"'21 U.S. C.§ 379h(g) (2006), U.S. Food and Drug Administration, supra note !61. 
115 Meeting notice, 76 Fed. Reg. 76738 {2011) {announcing "a public mee.Ung to discuss proposed 
recommendations for enactment of a Generic Drug User Fee Act (GDUFA)"). 
nu Kweder Statement,liupra note 5. 
mId. 
m HiU & ReiUy, supra note 6, at 4. 
"'11 U.S.C.§ 379h(a}(I)(F]. 
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market and generate shortages."' Congress has included liability protection for 
health care providers in various emergency preparedness initiatives,'" and I have 
argued in previous work for more extensive provider immunity in the specialized 
context of declared public health emergencies."' However, recent literature does 
not suggest that the current wave of shortages is attributable to concerns about 
liability.18·1 Consequently, legislation altering tort liability would not be justified at 
this time. If liability concerns emerge as a major cause of drug shortages in the 
future, policy-makers could consider narrowly-tailored protections in response to 
the circumstances at issue. 
Private parties may also be able to contribute to shortage prevention through 
contract terms. Providers may include strong failure-to-supply requirements in 
their contracts in order to deter manufacturer conduct that leads to shortages."' 
Failure-to-supply clauses require manufacturers to provide reimbursement for the 
difference between the agreed-upon sale price and the price at which the provider 
ultimately purchased the drug from another source. 1" Such provisions have been 
successfully used by some health care entities to recoup significant costs.'" 
VI. CoNcLUSION 
The drug shortage crisis is ongoing and serious. It jeopardizes the lives of untold 
numbers of patients and causes anxiety and !Ilisery for patients and health care 
providers alike. The crisis has not escaped attention at the highest levels of govern-
ment, including Congress and the President of the United States. Commentators 
and policy-makers have not lacked for ideas as to how to address the problem, 
but measures implemented thus far have not been adequately comprehensive and 
potent to avert further scarcity. 
This Article argues that the drug shortage crisis should be treated as a public 
health threat that justifies forceful intervention. Because of the low level of price 
responsiveness in the health care market,"' the marketplace alone cannot correct 
the drug shortage problem. 
The crisis requires a multi-faceted offensive involving legislative, regulatory, and 
private sector changes. Public health policies and standards must serve multiple 
roles: they should deter both carelessness that leads to product contamination and 
purposeful decisions to discontinue or suspend manufacturing when such decisions 
will cause shortages, and at the same time, they should encourage production of 
vulnerable drugs. 
To that end, the article recommends that the "Preserving Access to Life-Saving 
Medications Act of 2011" be passed at the earliest opportunity. Congress should 
add a provision requiring manufacturers to report all drug shortages along with 
liO Noah, supra note 144, at 767~70 (suggesting implementation of a model based on the workers' 
compensation system or a "regulatory compJiance defe:Jse."). 
111 Hoffman, supra note 105, at 1941-46. 
1!2 Jd. at 1959-61. 
IU See supra Part ll, 
1114 Haninger et al., supra note 61 at 15; Glied Statement, supra note 51, 
IH Giied Statement, supra note 51 (noting that "faiiure-to~supply clauses, however, provide no 
reimbursement if there are no alternative sources for the drug. do not reimburse for resources expended 
looldng for other sources. and are of limited duration ... ). 
l!ti Alveo Weil, Failure-to-Supply Pharmacy Program Saves Hospitals More than !.3.5 Million by 
Attacking Drug Shortage Problems, at h.tlp:l/www.premierinc.com/aboutlnews/IO-dedftsl209!0.jsp. 
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explanations of their causes so that the problem can be better analyzed and under-
stood. The FDA should ask applicants for drug approval to indicate whether they 
will create redundancy in manufacturing capacity to avoid shortages, and if so, 
how. The agency should regard such plans favorably during its application review 
process. Furthermore, the FDA could consider a past history of causing an avoidable 
shortage as an adverse indicator if the manufacturer seeks approval of a new drug. 
Additional components of the drug shortage solution are changes to the Medicare 
reimbursement system and DEA quotas for scarce controlled substances. Shortages 
should also be deterred through financial incentives for production of vulnerable 
or scarce drugs, including tax benefits, user fee adjustments, and failure-to-supply 
clauses. These recommendations are not necessarily exhaustive, and others should 
be carefully considered as they emerge. 
Excessively aggressive approaches that are hostile to manufacturers and under-
mine their interests should be rejected. Although it is ironic that inexpensive drugs 
that are preferred by patients are often the ones in short supply,'" manufacturers 
cannot be expected to produce generic drugs if those drugs will be unprofitable for 
them. Policy-makers must make every effort to formulate balanced solutions that 
take the welfare of all stakeholders into account. As emphasized by Jay Cuetara, 
a cancer patient who experienced a drug shortage during his illness, health care 
providers, industry and the government must work together to ensure that patients 
"have access to the best critical drug at the right time and every time it's needed. nJslJ 
lBS FDA Workshop, supra note 1, at99. 
m Id. at 101. 
